Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$681.06M
Close$
$-31.51
181.4% downside
Current Fair Value
181.4% downsideOvervalued by 181.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $681.06 Million |
|---|---|
| Enterprise Value | $702.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.13 |
| Outstanding Shares | 18,412,000 |
Return
| Return on Equity | 91.08% |
|---|---|
| Return on Assets | 72.18% |
| Return on Invested Capital | 29.72% |
Valuation & Multiples
| P/E Ratio | 1.83 |
|---|---|
| PEG | -7.52 |
| Price to Sales | 2.42 |
| Price to Book Ratio | 1.84 |
| Enterprise Value to Revenue | 2.34 |
| Enterprise Value to EBIT | 5.69 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$55.27 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 74.32% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.44%▼ 85.48% |
|---|---|
| Total Invested | $10.34M▼ 97.61% |
| Investors Holding | 27▼ 128.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez